Philippe Fauchet
Vermogen: 219 225 $ op 31-10-2026
Vermogen: 219 225 $ op 31-10-2026
Philippe Fauchet currently works at Rezolute, Inc., as Independent Director from 2020, Noile-Immune Biotech, Inc., as Independent Outside Director from 2020, Luca Science, Inc., as Outside Director from 2022, and 4BIO Ventures Management Ltd., as Venture Partner & Japana6 from 2019.
Mr. Fauchet also formerly worked at GlaxoSmithKline KK, as Chairman from 2018 to 2019, JCR Pharmaceuticals Co., Ltd., as Independent Outside Director from 2013 to 2026, and Sanofi-Aventis Groupe SA, as Senior VP & Head-Corporate Business Development.
Mr. Fauchet received his graduate degree from École des Hautes Études Commerciales de Paris and undergraduate degree from Université Paris Nanterre.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
REZOLUTE, INC. 0,06% | 05-10-2026 | 55.500 ( 0,06% ) | 219 225 $ | 31-10-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| REZOLUTE, INC. | Directeur/Bestuurslid | 10-09-2020 |
| NOILE-IMMUNE BIOTECH INC. | Directeur/Bestuurslid | 01-03-2020 |
| JCR PHARMACEUTICALS CO., LTD. | Directeur/Bestuurslid | 01-06-2022 |
Luca Science, Inc.
Luca Science, Inc. BiotechnologyHealth Technology Develops mitochondrial transplantation therapy for mitochondrial diseases | Directeur/Bestuurslid | 01-06-2022 |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management invests in companies located in the United Kingdom. The firm targets companies operating in the fields of gene therapy, cell theray, RNA based therapy, targeted therapies and microbiome. They provide financing for early stage capital requirements. | Private Equity Investor | 01-01-2019 |
| Bedrijven | Functie | Einde |
|---|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Directeur/Bestuurslid | 15-09-2026 |
GlaxoSmithKline KK
GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables Researches, develops, imports, manufactures and sells toiletry products | Voorzitter | 01-02-2019 |
Sanofi-Aventis Groupe SA
Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Functions as an investment holding company | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 9 |
|---|---|
GlaxoSmithKline KK
GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables Researches, develops, imports, manufactures and sells toiletry products | Consumer Non-Durables |
JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and sells ethical drugs and regenerative medicine | Health Technology |
École des Hautes Études Commerciales de Paris
École des Hautes Études Commerciales de Paris Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université Paris Nanterre
Université Paris Nanterre Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rezolute, Inc.
Rezolute, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for metabolic diseases related to chronic glucose imbalance | Health Technology |
Sanofi-Aventis Groupe SA
Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Noile-Immune Biotech, Inc.
Noile-Immune Biotech, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of CAR-T cell therapy based therapeutic cancer drugs | Health Technology |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management invests in companies located in the United Kingdom. The firm targets companies operating in the fields of gene therapy, cell theray, RNA based therapy, targeted therapies and microbiome. They provide financing for early stage capital requirements. | Finance |
Luca Science, Inc.
Luca Science, Inc. BiotechnologyHealth Technology Develops mitochondrial transplantation therapy for mitochondrial diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau